🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Technology Sector SEC Filings — March 17, 2026

Across the 8 filings in the USA S&P 500 Technology stream, dominant themes include advancing SPAC de-SPAC mergers (AParadise with Enhanced Games, dMY Squared with Horizon Quantum) and bank-tech adjacent mergers (Community West Bancshares), alongside restructuring at PSQ Holdings with strong revenue growth but cash burn, proxy preparations at Altimmune, and shelf registration post-divestitures at Planet Green. Period-over-period trends highlight PSQ's revenue surge (+81% FY YoY, +109% Q4 YoY) and loss improvements (-37% FY net loss YoY), contrasted by sharp cash declines (-59% YoY to $14.6M) and equity drops (-50% to $13.4M), with no other filings showing financial metrics but positive merger progress. Critical developments like regulatory approvals, shareholder votes, and 2026 event timelines (e.g., Enhanced Games May 2026) signal near-term catalysts amid mixed sentiment (4 positive, 3 mixed, 1 neutral). Portfolio-level patterns reveal M&A momentum in 4/8 filings, operational restructurings for cost savings (PSQ staff cuts >40%, $8M annualized savings), and divestitures of underperformers (Planet Green), implying sector focus on consolidation and efficiency despite cash pressures. Market implications favor event-driven trades around Q1-Q2 2026 catalysts, with relative outperformance in revenue growers like PSQ vs. stagnant peers.

4 high priority 4 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 17, 2026

Across the 8 NASDAQ-100 related filings dated March 17, 2026, dominant themes include M&A momentum with SPAC and bank mergers advancing toward Q2 2026 closures, explosive post-acquisition revenue growth at IPM (2050% YoY to $23.6M FY2025), and early product wins like AITX's order, contrasted by mixed profitability signals and routine governance actions. Period-over-period trends highlight IPM as a hypergrowth outlier with Q4 revenue +2092% YoY to $6.1M but -1.7% QoQ decline, net losses improving 77% YoY to $2.0M annually, positive Q4 Adjusted EBITDA of $5K, and operating cash flow turning positive; no comparable metrics in other filings limit broader aggregation but underscore IPM's relative outperformance. Critical developments like regulatory approvals for CWBC-USB merger and AParadise-Enhanced Games $1.3B combination signal near-term catalysts, while IPM's $400K buyback (76% executed) and zero long-term debt reflect prudent capital allocation. Portfolio-level patterns show 4/8 filings positive on growth/M&A, 2 mixed on IPM's losses/litigation, and 2 neutral on governance/shelf, implying bullish M&A tailwinds but watch for dilution/integration risks. Overall, actionable intelligence favors positioning ahead of March-April shareholder votes and May 2026 Enhanced Games debut, with IPM as a high-beta turnaround play.

4 high priority 4 medium 8 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 17, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (March 17, 2026), dominant themes include robust M&A and SPAC activity in finance (e.g., bank mergers like United Security/Community West and Two Harbors/UWM), explosive revenue growth in energy storage (Energy Vault +340% YoY) and select tech/biotech, offset by margin compression and net loss widening in 12/50 companies averaging -25% YoY net income growth where reported. Period-over-period trends show 18 companies with revenue growth >20% YoY (avg +85%), but 14 with margin contraction (avg -250 bps) and 10 with cash burn acceleration (avg +35% YoY); banks exhibit deposit growth (+36% YoY Mechanics) amid NIM stability/declines. Forward-looking catalysts cluster in Q2 2026 (e.g., merger closings, Phase 3 trials), with capital allocation favoring debt refinancings (Indivior $500M notes) and buybacks/dividends ($1.69B CF Industries returns). Mixed sentiment prevails (28/50), signaling portfolio-level caution on profitability amid growth; outliers like BW Industrial IPO ($17.1M proceeds) and Vireo M&A highlight alpha in industrials/cannabis. Implications: Rotate into high-backlog growth (Energy Vault $1.3B) and monitor bank consolidations for synergies, while hedging media/tech declines (Urban One -16% rev, Baidu -3%).

30 high priority 20 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 17, 2026

Across 50 SEC filings dated March 17, 2026, dominant themes include active SPAC mergers/de-SPACs (e.g., AParadise/Enhanced Games, Tri Pointe/Sumitomo, Pelican/Greenland), biotech advancements (Monte Rosa positive Phase 1 data, Cortigent IPO for brain implants), and retail/industrial turnarounds (Citi Trends +9% YoY sales, Ethos +52% revenue), contrasted by mixed financials (Mechanics Bancorp +817% net income from merger gain but rising provisions) and infrastructure stability (Brookfield +9.8% revenue). Period-over-period trends show revenue growth averaging +20% YoY in reporting firms (e.g., Citi Trends +8.9% FY sales, Dragonfly +15.8% FY), but margin pressures in 4/8 cases (Dragonfly -260bps FY gross margin, PURE mixed product lines) and net losses narrowing in biotechs/small caps (PURE -16% 6m loss). Capital allocation leans conservative (Citi Trends zero debt, Dragonfly $8.9M cost savings), with forward-looking catalysts like IPOs, FDA milestones, and merger votes driving near-term volatility. Portfolio-level patterns highlight biotech/healthcare outperformance (5/7 positive/mixed with clinical wins) vs neutral proxy/compliance noise (15+ ABS 10-Ks). M&A activity signals consolidation in homes/financials, while emerging IPOs (Cortigent $15M, BW Industrial $17M) offer growth entry points amid controlled company structures.

38 high priority 12 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 17, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector context from retail, hotels, airlines, and adjacent), key themes include robust revenue growth in 8/14 reporting companies (avg +45% YoY, led by Dragonfly +15.8%, Fold +34%, Marwynn +122%) offset by widespread margin compression (avg -200bps) and widening losses (e.g., Fold op loss to $27.7M, SafeSpace -41% YoY), signaling cost pressures amid RV/auto softness and ops disruptions. Capital allocation remains shareholder-friendly with new buybacks ($250M First Industrial, Kforce 10b5-1 plan, CF $1.37B repurchases), steady dividends (Waterstone quarterly, First Guaranty 131st consecutive), and M&A activity ($800M+ Infinity upstream, Fulgent $56.9M assets, Farmer Bros merger). Proxy season ramps up with 15+ AGMs in April-May 2026, highlighting board refreshers and comp votes. Forward guidance mixed: Dragonfly targets EBITDA positivity at $70M run-rate, Frontier Q1 loss $0.32-0.44 amid fuel spikes. Portfolio-level: 6/10 high-materiality filings show mixed sentiment, with hotels/entertainment stable but airlines volatile; actionable now on buybacks amid undervalued growth names.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 17, 2026

Across 41 diverse SEC filings labeled under USA S&P 500 Healthcare (though spanning retail, biosciences, energy, finance, and more), overarching themes include modest revenue growth averaging ~12% YoY in 8/41 reporting companies (e.g., Lifeway +14%, PURE Bioscience +22%, Zeo +33%), offset by persistent net losses in biosciences and cash burn concerns; margin expansions noted in standouts like Citi Trends (+210bps FY to 39.6%) and Lifeway (+140bps to 27.4%). Healthcare-adjacent biosciences (7 filings) show revenue up avg 15% YoY but mixed sentiment with narrowing losses (PURE -16%, Cibus -53%) amid clinical catalysts and M&A (Rallybio merger). Capital allocation leans toward buybacks (News Corp $1B program, New Peoples 500k shares) and dividends (Waterstone quarterly), while energy names like New Fortress face severe restructuring (debt cut to $527.5M, shareholder dilution to 35%). Critical developments: bioscience efficiency gains and product launches (Cibus rice traits 2027-28), SPAC mergers for growth (Abra $10B AUM target 2027), but restatements/restatements signal control weaknesses. Portfolio implications: selective opportunities in high-growth biosciences/turaround retail, caution on cash-strapped microcaps and leveraged restructurings.

19 high priority 22 medium 41 total filings
· daily

Global High-Priority Regulatory Events — March 17, 2026

The 50 filings reveal a surge in SPAC/de-SPAC activity (10+ filings including Black Hawk/Vesicor, AParadise/Enhanced Games, Pelican/Greenland) with promotional interviews, extension notes, and merger progress amid positive sentiment for biotech/sports innovations. Indian insolvency events dominate critically (Jaiprakash Adani resolution with shareholder wipeout, Hindustan Zinc 55.83% promoter encumbrance, Videocon/Sumeet/Value CIRP updates), signaling distressed asset opportunities but promoter control risks. Financial trends mixed: standout revenue growth (Ethos +52% YoY to $387.6M, Mechanics Bancorp NI +817% YoY to $266M post-merger, Xerox +12.9% to $7B, McEwen +13%), but margin compressions (Xerox -4.4pts to 27.1%, Brookfield op cash -8%) and debt piles (PURE $5.52M convertibles, American Rebel 15% note). Biotech/medical advances bullish (Vesicor CEO hire, Tenon $4.3M raise, NeOnc CAO), IPOs/S-1s active (Cortigent brain implants $4-6B TAM, BW Industrial $17M), capital allocation favors buybacks (First Industrial $250M). Portfolio patterns: SPAC catalysts near-term, Indian miners bearish leverage, US small caps growth via M&A/debt; implications for alpha in de-SPACs, caution on distress.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 17, 2026

The IPO Pipeline stream on March 17, 2026, captures two high-materiality filings: Rallybio Corp's S-4 for its merger with Candid Therapeutics (mixed sentiment) and AmperCap Acquisition Company's S-1 for a $125M SPAC IPO (neutral sentiment). Both entities exhibit no revenues to date, reflecting pre-operational stages with zero YoY/QoQ revenue growth and flat operational metrics, underscoring high-risk development plays. Rallybio's merger includes CVRs tied to a July 8, 2025, Recursion Pharmaceuticals deal, introducing contingent value amid post-merger compliance hurdles like 12-month Form S-3 ineligibility. AmperCap's SPAC structure deposits proceeds into a trust for a 24-month business combination window, with $2.5M underwriting discounts and $4M working capital needs. Portfolio-level patterns show biotech M&A activity intersecting with SPAC launches, signaling potential thaw in risk-on IPO markets. Critical implications include merger catalyst timing for Rallybio and SPAC pricing appetite for AmperCap, with no insider activity or capital allocation trends reported across filings.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — March 17, 2026

Across 50 SEC filings for Q4 2025/FY2025 financial results filed March 17, 2026, sentiment is predominantly mixed (25+ filings) with neutral ABS servicing compliance dominating low-materiality disclosures (15+ filings), signaling routine stability in asset-backed securities servicing but no major issues. Revenue growth trends are uneven: strong outperformers like Ethos Technologies (+52% YoY to $387.6M), Xerox (+12.9% to $7.0B), and HealthEquity (+9% to $1.31B) contrast with decliners like NextNav (-19.3%), IZEA (-13%), and Gossamer Bio (-58%), averaging modest portfolio-level growth of ~15% YoY among high-materiality names. Margin compression is widespread (e.g., Xerox gross margin -440bps to 27.1%, Academy SG&A +820bps to 26.3%), offset by loss narrowing in biotechs (Monte Rosa -47% to $38.6M loss, AN2 -31% to $35.2M) and banks (Mechanics +817% net income post-merger). Capital allocation leans conservative with dividends up in Value Line (+8% nine-month payout to $9.2M) but dilution rampant via equity raises (X4 shares +1495% to 90.9M, Oklo cash +712% to $788M). SPACs like M3-Brigade and ProCap show passive interest income gains ($4.15M, $5.66M) amid no business combinations. Biotech/pharma heavy (12 filings) highlights R&D spend persistence despite cuts, while banking/mining exhibit asset expansion but yield pressures; actionable theme is selective rotation to revenue accelerators like DTC/tech amid macro caution.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 17, 2026

Across 38 DEF 14A filings filed March 17, 2026, a dominant theme is robust 2025 performance recaps with YoY growth in key metrics—e.g., Rollins double-digit revenue/earnings/cash flow (24th consecutive revenue growth year), CF Industries net earnings $1.46B (+implied strong YoY), Archrock NI +87% YoY/EBITDA +51% YoY/margins +600bps, Ball Corp record $13.16B sales/EVA/FCF/EPS—contrasting with mixed outlooks in cyclicals like Boise Cascade (flat 2026 construction) and Polaris (headwinds/divestiture). Capital allocation emphasizes shareholder returns totaling billions (CF $1.69B buybacks/dividends, Global Payments $1.5B, Archrock $212M), signaling management conviction amid neutral-to-positive sentiment (11 positive, 4 mixed). Governance highlights include board refreshes (e.g., T. Rowe Price +2 independents, Global Payments +3), independent majorities (e.g., Ball 8/9, AutoNation independent Chair), and standard proposals for elections/say-on-pay/auditors, with 20+ virtual meetings April-May 2026 as catalysts. No widespread insider selling detected; director ownership increases noted (Gran Tierra DSUs/PSUs YoY up). Portfolio-level: Industrials/energy outperform (6/10 positive), SPACs/cyclicals lag; pay-vs-performance XBRL disclosures (15+ filings) show alignment without major declines. Implications: Favor high-return firms pre-vote catalysts, monitor extensions/divestitures for downside.

38 high priority 38 total filings
· daily

US Executive Officer Management Changes SEC — March 17, 2026

Across 44 SEC filings on US executive and director changes from March 17, 2026, a net positive shift emerges with 22 appointments/promotions (51%) outpacing 20 resignations/retirements (45%), predominantly neutral but tilted positive in healthcare/biotech/tech sectors via high-caliber hires like ex-Air Force official at Redwire and Stryker CEO at GE HealthCare. Period-over-period trends in enriched data show robust revenue acceleration in biotechs (Bicycle Therapeutics +94% YoY Q4 collab rev to $48M, Neuronetics +86% YoY Q4 to $41.8M, +99% FY to $149.2M) but margin compression (Neuronetics gross margin -2370 bps YoY to 48.5%) and net losses widening (Bicycle FY -219M vs -169M). Critical developments include clustered resignations by Susan B. McGee from 6+ Goldman-related entities (filings 20-24,44), signaling potential portfolio consolidation, and Gran Tierra's 4-director exodus over audit disputes (filing 31). Capital allocation highlights include First Industrial's new $250M buyback (filing 3) and equity grants/RSUs across Coursera, Hinge Health, NWPX (filings 16,11,43). Forward-looking catalysts feature Neuronetics FY2026 rev guidance $160-166M, Cencora reaffirmed FY2026 adj EPS $17.45-17.75, and multiple AGMs Q2 2026. Portfolio implications: Favor firms with strategic hires amid transitions; monitor governance risks in energy/financials for volatility.

44 high priority 44 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 17, 2026

Across 42 filings in the USA Corporate Distress & Bankruptcy stream, dominant themes include aggressive liquidity maneuvers via high-cost convertible notes, equity offerings, and debt restructurings (e.g., 10+ issuances of notes/preferred with 15-22% effective rates), Nasdaq compliance failures (4 cases with delisting/reverse split risks), and covenant amendments signaling near-term stress, amid limited explicit YoY/QoQ data but clear patterns of debt settlements reducing burdens (e.g., Integrated Rail settled $705k, i-80 Gold retired $165M). Positive offsets feature major contracts (Duos $176M over 36 months), grants (Clene $8M), and M&A (Public Storage acquiring NSA), with sentiments skewing positive/neutral in 70% of cases despite distress focus. Critical developments like Urgent.ly's imminent delisting and New Fortress Energy's RSA (diluting shareholders to 35%) heighten bankruptcy risks, while refinancings (Indivior $500M at 0.625%, Beazer +43.8% facility) provide relief. Portfolio-level: Small-cap biotechs/tech show repeated dilution/equity raises (12 cases), airlines/construction deferrals indicate capex cuts, no broad margin compression trends evident but liquidity covenants relaxed in 3 filings. Implications: Heightened short opportunities in non-compliant names, long setups in turnaround financings with catalysts.

42 high priority 42 total filings
· daily

US SEC Trading Suspension Halt Orders — March 17, 2026

Nasdaq listing compliance challenges dominate the USA Trading Suspensions stream, with Urgent.ly Inc. facing trading suspension on March 18, 2026, and delisting due to failure to meet net income requirements under Rule 5550(b) by the March 16 deadline, despite a March 13 merger agreement with Agero. Fractyl Health received a bid price deficiency notice under Rule 5450(a)(1) on March 13, with 180 days to cure by September 9, 2026, highlighting ongoing liquidity risks for small caps. In contrast, Incannex Healthcare cured its prior bid price deficiency under Rule 5550(a)(2) as of March 16, maintaining $1.00+ closes for 11 consecutive business days from February 27 to March 13, resolving overhangs from 2025 filings. No explicit period-over-period financial trends across filings, but Incannex outperforms with $75M cash, zero debt, and positive Phase 2 clinical data versus peers' regulatory distress. Mixed sentiment overall (1 positive, 1 negative, 1 mixed), with healthcare names (Fractyl, Incannex) showing bid price volatility patterns. Portfolio implications include heightened delisting risks reducing trading volumes, potential OTC transitions, and merger catalysts as offsets. Actionable theme: monitor tender offers and compliance deadlines for short-term trading opportunities.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 17, 2026

Across 44 SEC filings on USA Board Room Changes dated March 17, 2026, the dominant theme is extensive board and executive reshuffles, with 22 appointments/promotions (e.g., new directors/CEOs/CFOs) versus 20 resignations/retirements, 80% neutral sentiment but positive tilt from high-profile adds in healthcare/tech (e.g., Redwire, GE HealthCare, Neuronetics). Period-over-period trends in disclosed financials show robust revenue growth in biotechs (Bicycle Therapeutics +37.3% FY YoY to $72.6M, Neuronetics +99% FY to $149.2M) but margin compression (Neuronetics gross margin -2370 bps to 48.5%) and mixed net losses. No widespread insider selling detected, but capital allocation shines with First Industrial's new $250M buyback (no expiration) and DLH's equity plan expansion approved. Healthcare/biotech leads with 12 changes signaling stabilization amid R&D/cash runway extensions to 2030; energy flags risks from Gran Tierra's 4-director exodus over audit disputes. Portfolio implication: monitor succession risks in mature firms (e.g., Cencora CFO retire June 2026) versus growth refreshes offering alpha.

44 high priority 44 total filings
· daily

US Merger & Acquisition SEC Filings — March 17, 2026

The 15 filings reveal a robust wave of M&A and takeover activity dominated by SPAC/deSPAC transactions (9/15 filings), with amendments, financings, and adjournments signaling persistent deal-making amid delays. Completed mega-deals include Alexander & Baldwin's $2.3B take-private at $21.20/share, IBM's $11B acquisition of Confluent at $31/share, and Fulgent's $56.9M asset buys, highlighting strong buyer appetite in real estate, tech/AI, and diagnostics. Positive sentiment prevails (8/15 positive, 4 neutral, 3 mixed), with no reported period-over-period financial declines or metric compressions across filings; instead, forward-looking catalysts like Q2 2026 revenue ramps and IND submissions dominate. SPAC extensions (e.g., Israel Acq to Apr 15) and bridge notes indicate capital raises to bridge to closings, while fresh IPOs like GalaxyEdge's $115M raise underscore new liquidity. Portfolio-level pattern: 6/15 filings involve procedural advances (amendments/adjournments) without financial revisions, suggesting stable valuations but timing risks. Overall, bullish M&A momentum implies sector rotation opportunities into targets and acquirers, with catalysts clustered in late March.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 17, 2026

Overnight SEC filings from March 16-17, 2026 reveal mixed financial performance across sectors, with standout YoY revenue growth in select names like Mechanics Bancorp (+817% net income post-merger), Ethos Technologies (+52% revenue), and PURE Bioscience (+21.7% six-month revenue), contrasted by margin compressions in Dragonfly Energy (-250 bps gross margin QoQ) and Xerox Holdings (-440 bps total gross margin). SPAC and M&A activity dominates with positive sentiment around AParadise/Enhanced Games merger ($1.3B valuation), Pelican/Greenland energy deSPAC, and Two Harbors/UWM acquisition push, while activist pressure mounts at Lululemon via Dennis Wilson's 8.4% stake and board criticism. Capital allocation trends favor buybacks (First Industrial $250M program) and debt settlements (Integrated Rail), but dilutive financings (American Rebel 15% effective note, Hammer related-party loans) raise dilution risks. Forward-looking catalysts include BioCardia FDA pre-submission acceptance, Dragonfly Q1 2026 guidance ($9.5M sales, -$4.6M Adj EBITDA), and multiple proxy meetings (Carlisle April 29). Routine ABS servicing compliance in 10+ 10-Ks signals stable RMBS/ABS operations with no material issues. Portfolio-level, 7/15 high-materiality filers show revenue growth averaging +25% YoY but mixed profitability, favoring opportunistic plays in SPACs and post-merger banks amid pre-market positioning.

39 high priority 11 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 16, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector context), dominant themes include steady capital returns via dividends (Benchmark $0.17/shr, Pebblebrook $0.01 common + prefs, Coca-Cola resilient outlook), frequent leadership transitions signaling strategic shifts (KORU CEO retirement 6/30/26, Helmerich CFO 6/30/26, Coca-Cola CEO to Henrique Braun), and mixed financials with revenue acceleration in 8/18 reporting companies averaging +32% YoY (Telos +52%, Gilat +48%, OPAL +16%) offset by margin compression in 7/12 cases averaging -380bps (Gilat -700bps, Dell products -210bps). Period-over-period trends reveal improving cash flows in turnarounds (Telos op CF +$56.1M to $30.2M, Comtech H1 +$34.9M to $12.9M) but widening losses in 6/15 small caps (KEEMO -62% worse, FutureFuel rev -61%). Forward-looking catalysts cluster in Q2-Q3 2026 (DuPont aramids sale 4/1, Black Diamond GBM trial Q2, Rafael topline Q3), with OPAL's 2026 EBITDA guidance $95-110M as a growth beacon. Portfolio implications favor selective longs in high-growth outliers like OPAL/Telos amid sector volatility, with watch for M&A closes and trial readouts driving alpha.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 16, 2026

Across 50 filings in the USA S&P 500 Industrials stream, key themes include robust revenue acceleration in power/infrastructure plays like Forgent Power Solutions (+69% YoY to $296M Q2, bookings +268%) and WaterBridge (+66% YoY to $525.6M FY25), offset by volume pressures in defense (SAIC -5% YoY Q4) and machinery (Comtech -16% YoY Q2 sales). Aggregate period trends: 8/15 revenue-reporting firms showed +20%+ YoY growth (avg +55%), but 6/10 reported net losses or widened due to one-offs, impairments, and debt costs; margins resilient in 4 cases (Comtech +720bps, SAIC +20bps FY). Capital allocation bullish with $422M SAIC buybacks, Amphastar +$50M program, multiple dividend hikes/initiations (ServisFirst $0.38, WaterBridge $0.05). M&A active: Public Storage-NSA merger (multiple filings), Addentax Keemo acquisition. Banks exhibit NI surges (+45% PCB, +49% Orange County) but rising NPAs/NPLs (+69% PCB nonaccruals, +76% Orange NPLs). Forward-looking signals mixed: Forgent +73% FY26 guide vs SAIC -4-2% organic; catalysts cluster Mar-Apr AGMs/earnings and Q2 2026 BLAs. Actionable: overweight infra growth, monitor credit deterioration.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 16, 2026

Across the 8 S&P 500 Energy stream filings (with some industrial/biotech outliers), key themes include robust revenue growth in 5/8 companies (e.g., Ampco-Pittsburgh +4% YoY FY sales to $434.2M, Stoke +404% YoY to $184M) offset by one-time losses and margin pressures, exemplified by Ampco's Q4 Adjusted EBITDA -47% YoY to $3.2M and FY operating loss of $(54.5M). Energy pure-plays shine: Marathon Petroleum (MPC) reported $4.0B 2025 net income, $12.0B adjusted EBITDA, 94% refining utilization, and $4.5B shareholder returns including 10% dividend hike to $1.00/share, while Dorchester Minerals secured $15.5M litigation settlement boosting April 2026 distributions. Capital allocation leans shareholder-friendly in energy (MPC $4.4B buyback authorization remaining), with forward-looking uplift from Ampco's UK facility exit ($7-8M annual EBITDA). Proxies signal routine governance (MPC DEFA14A/DEF14A, Peapack), but mixed sentiment prevails in 3/8 filings due to charges/backlog declines. Portfolio implications: Favor MPC/Dorchester for near-term yields; monitor Ampco/Stoke turnarounds amid Q4 weakness. Catalyst-rich: Earnings calls and AGMs in March-April 2026.

5 high priority 3 medium 8 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 16, 2026

Across 50 filings from S&P 500 Financials and related streams, overarching themes include mixed financial performance with revenue declines averaging -7% YoY in 14/25 reporting companies (e.g., Townsquare -5.2%, iQIYI -6.6%, LivePerson -22%) offset by aggressive cost reductions boosting operating income (e.g., Townsquare +103.8%) and EBITDA (WaterBridge +68% to $254M); notable M&A and capital markets activity like Kennedy-Wilson merger amendments requiring 2/3 vote excl. insiders, Armada Hoffler $562M asset sale, and MSC Income $150M notes. Fintech standouts like Figure Technology (+48.7% rev to $507M, +574% NI) and Blend Labs (+7% rev, op cash flow positive $14.4M) contrast with bank/insurer stability (PCB Bancorp +45% NI, AIG director exit neutral). Capital allocation favors buybacks (Amphastar +$50M) and dividends (Townsquare $0.20 qtrly, PCB +11%), while SPACs extend deadlines amid redemptions (Trailblazer to June 2026). Forward guidance mixed but growth-oriented (Townsquare FY2026 $420-440M rev, WaterBridge +7-9% EBITDA), signaling portfolio-level resilience amid sector rotation opportunities. Implications: Favor fintech/bank growth outliers, monitor merger votes and Q1 catalysts for alpha.

32 high priority 18 medium 50 total filings